{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:59:03Z","timestamp":1785110343094,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353900"],"award-info":[{"award-number":["RS-2024-00353900"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353900"],"award-info":[{"award-number":["RS-2024-00353900"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353900"],"award-info":[{"award-number":["RS-2024-00353900"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353900"],"award-info":[{"award-number":["RS-2024-00353900"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00353900"],"award-info":[{"award-number":["RS-2024-00353900"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-24534134"],"award-info":[{"award-number":["RS-2025-24534134"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-24534134"],"award-info":[{"award-number":["RS-2025-24534134"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003654","name":"MOE | Korea Environmental Industry and Technology Institute","doi-asserted-by":"publisher","award":["2022002980004"],"award-info":[{"award-number":["2022002980004"]}],"id":[{"id":"10.13039\/501100003654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003654","name":"MOE | Korea Environmental Industry and Technology Institute","doi-asserted-by":"publisher","award":["2022002980004"],"award-info":[{"award-number":["2022002980004"]}],"id":[{"id":"10.13039\/501100003654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003654","name":"MOE | Korea Environmental Industry and Technology Institute","doi-asserted-by":"publisher","award":["2022002980004"],"award-info":[{"award-number":["2022002980004"]}],"id":[{"id":"10.13039\/501100003654","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02856-5","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:01:05Z","timestamp":1785106865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-3258","authenticated-orcid":false,"given":"Seoyoon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8922-8645","authenticated-orcid":false,"given":"Dongjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1989-5886","authenticated-orcid":false,"given":"Haneul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-9014","authenticated-orcid":false,"given":"Deborah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1676-7607","authenticated-orcid":false,"given":"Lifeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7098-133X","authenticated-orcid":false,"given":"Stanislav Y.","family":"Emelianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-7768","authenticated-orcid":false,"given":"Jong-Ho","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-4473","authenticated-orcid":false,"given":"Yun Suk","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-637X","authenticated-orcid":false,"given":"Sun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-9040","authenticated-orcid":false,"given":"Tae-Joon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2856_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2856_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2856_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02632-y","volume":"24","author":"S Torabi","year":"2025","unstructured":"Torabi, S. et al. Immune cell-based therapies for solid tumors, current challenges and therapeutic advances. Cell Commun. Signal. 24, 73 (2025).","journal-title":"Cell Commun. Signal."},{"key":"2856_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2856_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson, N. R., Minutolo, N. G., Gill, S. & Klichinsky, M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201\u20131208 (2021).","journal-title":"Cancer Res."},{"key":"2856_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 6, 291 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2856_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/CMR.00046-08","volume":"22","author":"TH Mogensen","year":"2009","unstructured":"Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240\u2013273 (2009).","journal-title":"Clin. Microbiol. Rev."},{"key":"2856_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s44222-024-00193-2","volume":"2","author":"J Nam","year":"2024","unstructured":"Nam, J. et al. Engineered polysaccharides for controlling innate and adaptive immune responses. Nat. Rev. Bioeng. 2, 733\u2013751 (2024).","journal-title":"Nat. Rev. Bioeng."},{"key":"2856_CR9","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41565-022-01225-x","volume":"17","author":"K Yang","year":"2022","unstructured":"Yang, K. et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat. Nanotechnol. 17, 1322\u20131331 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"2856_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41551-024-01194-7","volume":"8","author":"DY Lee","year":"2024","unstructured":"Lee, D. Y. et al. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nat. Biomed. Eng. 8, 593\u2013610 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2856_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202306158","volume":"35","author":"J Liang","year":"2023","unstructured":"Liang, J. et al. Outer membrane vesicle-based nanohybrids target tumor-associated macrophages to enhance trained immunity-related vaccine-generated antitumor activity. Adv. Mater. 35, 2306158 (2023).","journal-title":"Adv. Mater."},{"key":"2856_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202206200","volume":"34","author":"Q Feng","year":"2022","unstructured":"Feng, Q. et al. Engineered bacterial outer membrane vesicles as controllable two-way adaptors to activate macrophage phagocytosis for improved tumor immunotherapy. Adv. Mater. 34, 2206200 (2022).","journal-title":"Adv. Mater."},{"key":"2856_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103497","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram tumor immunosuppressive microenvironment for enhanced chemo-immunotherapy. Adv. Mater. 33, 2103497 (2021).","journal-title":"Adv. Mater."},{"key":"2856_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu, A. et al. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct. Target. Ther. 9, 68 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2856_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41551-023-01031-3","volume":"7","author":"LJ Dooling","year":"2023","unstructured":"Dooling, L. J. et al. Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses. Nat. Biomed. Eng. 7, 1081\u20131096 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2856_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2856_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, 2103258 (2021).","journal-title":"Adv. Mater."},{"key":"2856_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah, Z. et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell 31, 803\u2013817 (2024).","journal-title":"Cell Stem Cell"},{"key":"2856_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"2856_CR20","doi-asserted-by":"publisher","first-page":"1640935","DOI":"10.3389\/fimmu.2025.1640935","volume":"16","author":"T Ding","year":"2025","unstructured":"Ding, T. et al. Comprehensive review of macrophage models: primary cells and immortalized lines across species. Front. Immunol. 16, 1640935 (2025).","journal-title":"Front. Immunol."},{"key":"2856_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"2856_CR22","doi-asserted-by":"publisher","first-page":"662063","DOI":"10.3389\/fimmu.2021.662063","volume":"12","author":"YL Fu","year":"2021","unstructured":"Fu, Y. L. & Harrison, R. E. Microbial phagocytic receptors and their potential involvement in cytokine induction in macrophages. Front. Immunol. 12, 662063 (2021).","journal-title":"Front. Immunol."},{"key":"2856_CR23","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. A small secreted protein triggers a TLR2\/4-dependent inflammatory response during invasive Candida albicans infection. Nat. Commun. 10, 1015 (2019).","DOI":"10.1038\/s41467-019-08950-3"},{"key":"2856_CR24","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1128\/IAI.73.8.5212-5216.2005","volume":"73","author":"R Dziarski","year":"2005","unstructured":"Dziarski, R. & Gupta, D. Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: a reevaluation. Infect. Immun. 73, 5212\u20135216 (2005).","journal-title":"Infect. Immun."},{"key":"2856_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev.biochem.71.110601.135414","volume":"71","author":"CRH Raetz","year":"2002","unstructured":"Raetz, C. R. H. & Whitfield, C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635\u2013700 (2002).","journal-title":"Annu. Rev. Biochem."},{"key":"2856_CR26","doi-asserted-by":"crossref","unstructured":"Tan, A. et al. Evasion of toll-like receptor recognition by Escherichia coli is mediated via population level regulation of flagellin production. Front. Microbiol. 14, 1093922 (2023).","DOI":"10.3389\/fmicb.2023.1093922"},{"key":"2856_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.172","volume":"49","author":"IA Hajam","year":"2017","unstructured":"Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C. & Lee, J. H. Bacterial flagellin-a potent immunomodulatory agent. Exp. Mol. Med. 49, e373 (2017).","journal-title":"Exp. Mol. Med."},{"key":"2856_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1021\/acssynbio.4c00483","volume":"14","author":"MY Chen","year":"2025","unstructured":"Chen, M. Y. et al. Endotoxin-free outer membrane vesicles for safe and modular anticancer immunotherapy. ACS Synth. Biol. 14, 148\u2013160 (2025).","journal-title":"ACS Synth. Biol."},{"key":"2856_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101400","volume":"43","author":"T Li","year":"2022","unstructured":"Li, T. et al. Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy. Nano Today 43, 101400 (2022).","journal-title":"Nano Today"},{"key":"2856_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.97","volume":"45","author":"BS Park","year":"2013","unstructured":"Park, B. S. & Lee, J. O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 45, e66 (2013).","journal-title":"Exp. Mol. Med."},{"key":"2856_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41551-024-01191-w","volume":"8","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics. Nat. Biomed. Eng. 8, 561\u2013578 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2856_CR32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acscentsci.8b00823","volume":"5","author":"TJ Albin","year":"2019","unstructured":"Albin, T. J. et al. Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses. ACS Cent. Sci. 5, 1137\u20131145 (2019).","journal-title":"ACS Cent. Sci."},{"key":"2856_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-014-0166-7","volume":"11","author":"K Rosenberger","year":"2014","unstructured":"Rosenberger, K. et al. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. J. Neuroinflammation 11, 166 (2014).","journal-title":"J. Neuroinflammation"},{"key":"2856_CR34","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: different gene signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).","journal-title":"Front. Immunol."},{"key":"2856_CR35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/ijms19020346","volume":"19","author":"R Kola\u0161inac","year":"2018","unstructured":"Kola\u0161inac, R., Kleusch, C., Braun, T., Merkel, R. & Csisz\u00e1r, A. Deciphering the functional composition of fusogenic liposomes. Int. J. Mol. Sci. 19, 346 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2856_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1021\/acscentsci.6b00172","volume":"2","author":"J Yang","year":"2016","unstructured":"Yang, J. et al. Drug delivery via cell membrane fusion using lipopeptide modified liposomes. ACS Cent. Sci. 2, 621\u2013630 (2016).","journal-title":"ACS Cent. Sci."},{"key":"2856_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","volume":"16","author":"JJ Rennick","year":"2021","unstructured":"Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266\u2013276 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2856_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.devcel.2006.04.002","volume":"10","author":"E Macia","year":"2006","unstructured":"Macia, E. et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839\u2013850 (2006).","journal-title":"Dev. Cell"},{"key":"2856_CR39","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1073\/pnas.211341698","volume":"98","author":"A Ros-Baro","year":"2001","unstructured":"Ros-Baro, A. et al. Lipid rafts are required for GLUT4 internalization in adipose cells. Proc. Natl. Acad. Sci. USA. 98, 12050\u201312055 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2856_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41420-025-02566-x","volume":"11","author":"H Masuda","year":"2025","unstructured":"Masuda, H. Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review. Cell Death Discov. 11, 341 (2025).","journal-title":"Cell Death Discov."},{"key":"2856_CR41","doi-asserted-by":"publisher","first-page":"1172681","DOI":"10.3389\/fimmu.2023.1172681","volume":"14","author":"S Das","year":"2023","unstructured":"Das, S., Valton, J., Duchateau, P. & Poirot, L. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Front. Immunol. 14, 1172681 (2023).","journal-title":"Front. Immunol."},{"key":"2856_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct. Target. Ther. 9, 142 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2856_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymeth.2007.11.008","volume":"44","author":"Z Darzynkiewicz","year":"2008","unstructured":"Darzynkiewicz, Z., Galkowski, D. & Zhao, H. Analysis of apoptosis by cytometry using TUNEL assay. Methods 44, 250\u2013254 (2008).","journal-title":"Methods"},{"key":"2856_CR44","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","volume":"41","author":"JC Osorio","year":"2023","unstructured":"Osorio, J. C., Smith, P., Knorr, D. A. & Ravetch, J. V. The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions. Cancer Cell 41, 2051\u20132065 (2023).","journal-title":"Cancer Cell"},{"key":"2856_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","volume":"18","author":"SM Jin","year":"2023","unstructured":"Jin, S. M. et al. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nat. Nanotechnol. 18, 390\u2013402 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"2856_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jconrel.2015.01.033","volume":"208","author":"EM Mastria","year":"2015","unstructured":"Mastria, E. M. et al. Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. J. Control. Release 208, 52\u201358 (2015).","journal-title":"J. Control. Release"},{"key":"2856_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202307694","volume":"20","author":"YJ Yoo","year":"2024","unstructured":"Yoo, Y. J. et al. Nanoengineered macrophages armed with TLR7\/8 agonist enhance remodeling of immunosuppressive tumor microenvironment. Small 20, 2307694 (2024).","journal-title":"Small"},{"key":"2856_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114389","volume":"388","author":"SN Lee","year":"2025","unstructured":"Lee, S. N. et al. Focused ultrasound-triggered doxorubicin liposomes reshape tumor microenvironment to boost checkpoint depletion in triple-negative breast cancer model. J. Control. Release 388, 114389 (2025).","journal-title":"J. Control. Release"},{"key":"2856_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3677-7","volume":"17","author":"WJ Aston","year":"2017","unstructured":"Aston, W. J. et al. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer 17, 684 (2017).","journal-title":"BMC Cancer"},{"key":"2856_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-025-00677-4","volume":"12","author":"R Karki","year":"2026","unstructured":"Karki, R., Netea, M. G., Diorio, C. & Kanneganti, T.-D. Cytokine storm. Nat. Rev. Dis. Prim. 12, 1 (2026).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2856_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1021\/accountsmr.2c00042","volume":"3","author":"J Ye","year":"2022","unstructured":"Ye, J., Hou, B., Saeed, M., Xu, Z. & Yu, H. Engineering bioinspired nanomedicines to mitigate the resistance to cancer immunotherapy. Acc. Mater. Res. 3, 697\u2013708 (2022).","journal-title":"Acc. Mater. Res."},{"key":"2856_CR52","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679\u2013692 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2856_CR53","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","volume":"12","author":"D Plana","year":"2022","unstructured":"Plana, D., Palmer, A. C. & Sorger, P. K. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 12, 606\u2013624 (2022).","journal-title":"Cancer Discov."},{"key":"2856_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"2856_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102365","volume":"57","author":"J Schunke","year":"2024","unstructured":"Schunke, J. et al. Co-delivery of STING and TLR7\/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+ T cell-mediated melanoma remission. Nano Today 57, 102365 (2024).","journal-title":"Nano Today"},{"key":"2856_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1021\/acscentsci.5b00274","volume":"1","author":"JK Tom","year":"2015","unstructured":"Tom, J. K. et al. Modulation of innate immune responses via covalently linked TLR agonists. ACS Cent. Sci. 1, 439\u2013448 (2015).","journal-title":"ACS Cent. Sci."},{"key":"2856_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","volume":"19","author":"G Liu","year":"2024","unstructured":"Liu, G. et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat. Nanotechnol. 19, 387\u2013398 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2856_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman, H., Silk, A. W., Kane, M. P. & Kaufman, H. L. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer 4, 53 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"2856_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae200","volume":"30","author":"K Runcie","year":"2025","unstructured":"Runcie, K. et al. Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. Oncologist 30, oyae200 (2025).","journal-title":"Oncologist"},{"key":"2856_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00842-8","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert, L. A. et al. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ Breast Cancer 11, 130 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"2856_CR61","doi-asserted-by":"publisher","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang, M., Hu, Y., Lin, G. & Chen, C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front. Oncol. 12, 906251 (2022).","journal-title":"Front. Oncol."},{"key":"2856_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00763-y","volume":"24","author":"GG Bitar","year":"2024","unstructured":"Bitar, G. G. et al. Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations. Cancer Imaging 24, 145 (2024).","journal-title":"Cancer Imaging"},{"key":"2856_CR63","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko, J. H. & Hollm\u00e9n, M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br. J. Cancer 131, 627\u2013640 (2024).","journal-title":"Br. J. Cancer"},{"key":"2856_CR64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1089\/apb.2024.0002","volume":"29","author":"P Gulig","year":"2024","unstructured":"Gulig, P., Swindle, S., Fields, M. & Eisenman, D. A review of clinical trials involving genetically modified bacteria, bacteriophages and their associated risk assessments. Appl. Biosaf. 29, 186\u2013206 (2024).","journal-title":"Appl. Biosaf."},{"key":"2856_CR65","doi-asserted-by":"publisher","first-page":"1140463","DOI":"10.3389\/fimmu.2023.1140463","volume":"14","author":"M Zhou","year":"2023","unstructured":"Zhou, M. et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front. Immunol. 14, 1140463 (2023).","journal-title":"Front. Immunol."},{"key":"2856_CR66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2856_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).","journal-title":"Science"},{"key":"2856_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2023","unstructured":"Zimmermannova, O. et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci. Immunol. 8, eadn4817 (2023).","journal-title":"Sci. Immunol."},{"key":"2856_CR69","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang, K., Halima, A. & Chan, T. A. Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol. 20, 604\u2013623 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2856_CR70","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.bbamem.2014.12.011","volume":"1848","author":"M Park","year":"2015","unstructured":"Park, M. et al. Isolation and characterization of the outer membrane of Escherichia coli with autodisplayed Z-domains. Biochim. Biophys. Acta Biomembr. 1848, 842\u2013847 (2015).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"2856_CR71","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"2856_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85329-9","volume":"11","author":"M Li","year":"2021","unstructured":"Li, M. et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Sci. Rep. 11, 5774 (2021).","journal-title":"Sci. Rep."},{"key":"2856_CR73","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215 (2015).","journal-title":"Nat. Med."},{"key":"2856_CR74","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1021\/acs.biomac.3c00528","volume":"24","author":"D Lee","year":"2023","unstructured":"Lee, D. et al. Multicomponent-loaded vesosomal drug carrier for controlled and sustained compound release. Biomacromolecules 24, 3898\u20133907 (2023).","journal-title":"Biomacromolecules"},{"key":"2856_CR75","doi-asserted-by":"publisher","unstructured":"Lemenze, A. MaGIC-Analytics\/Magic-Volcanoes: V1 Release. (2024). https:\/\/doi.org\/10.5281\/zenodo.10845738","DOI":"10.5281\/zenodo.10845738"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02856-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:01:21Z","timestamp":1785106881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02856-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02856-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"302"}}